Technology ID
TAB-3847

Multi Protein Nanoparticle Monkeypox Vaccine

E-Numbers
E-183-2022-0
Lead Inventor
Moss, Bernard (National Institute of Allergy and Infectious Diseases (NIAID/NIH))
Development Stages
Pre-Clinical (in vitro)
Lead IC
NIAID

In 2022, the World Health Organization declared an atypical outbreak of monkeypox (Mpox), which has caused approximately 30,000 cases of Mpox infection within the United States as of April 2023. Mpox represents a current threat to public health, and there is an immediate need for an effective vaccine. To address this, NIAID has developed a vaccine approach comprising virus-like nanoparticles coated with modified Mpox proteins. NIAID investigations have demonstrated that immunization has elicited a robust immune response in mice and provided protection against a lethal infection of Vaccinia virus.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

Competitive Advantages
  • A Mpox nanoparticle vaccine may have fewer side effects than available MVA based vaccines.
  • The storage and transport requirements of a Mpox nanoparticle vaccine are better suited to low resource settings than MVA vaccines.

Request More Info

Licensing Contact:
Hurley, Benjamin
benjamin.hurley@nih.gov

Related Inventions

Collaborations

  • Licensing
  • Collaboration

Collaboration Description

  • The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this invention.
Date Published